ERBB2 and breast cancer: The objectives of this study were to evaluate the possible correlation between TILs, hTERT expression, hTERT promoter mutation (C228T and C250T mutations), and leukocyte telomere length (LTL) with the response to neoadjuvant chemotherapy based on anthracycline-taxane-trastuzumab or fluorouracil-anthracycline-taxane-trastuzumab regimen (AC-T/FAC-T) in a retrospective Brazilian cohort from HER2-E breast cancer patients.